Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL304059 | 0.98 | CYP1A2 (0.50) | CYP1A2CYP17A1MKNK1MKNK2KMT2A | |
| SCHEMBL303982 | 0.86 | CYP17A1 (0.56) | CYP1A2CYP17A1MKNK1MKNK2KMT2A | |
| SCHEMBL305462 | 0.86 | CYP1A2 (0.49) | CYP1A2CYP17A1MKNK1MKNK2KMT2A | |
| SCHEMBL4573821 | 0.82 | MAPK14 (0.50) | CYP1A2CYP17A1MKNK1MKNK2KDM4E | |
| SCHEMBL25257558 | 0.81 | XDH (0.53) | CYP1A2CYP17A1MKNK1MKNK2RAB9A | |
| SCHEMBL304096 | 0.81 | XDH (0.53) | CYP1A2CYP17A1MKNK1MKNK2KMT2A | |
| SCHEMBL30491699 | 0.81 | XDH (0.53) | CYP1A2CYP17A1MKNK1MKNK2KMT2A | |
| SCHEMBL30491768 | 0.81 | XDH (0.53) | CYP1A2CYP17A1MKNK1MKNK2RAB9A | |
| Hydrochloric Acid SCHEMBL5551165 | 0.79 | MKNK1 (0.42) | CYP1A2CYP17A1MKNK1MKNK2SCN9A | |
| SCHEMBL13791629 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP17A1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| CN-109608449-A | Compound as type III receptor tyrosine kinase inhibitors | 阵列生物制药公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-105924437-B | Compound as type III receptor tyrosine kinase inhibitors | 阵列生物制药公司 | 2018-11-30 | — | — | CN | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| CN-105924437-A | Compounds As Type III Receptor Tyrosine Kinase Inhibitors | 阵列生物制药公司 | 2016-09-07 | — | — | CN | disclosed |
| CN-103347882-B | Substituted N- (1H-indazol-4-yl) imidazo [1,2-a ] pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9174981-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2651939-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2081910-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | CYP1A2 1836/4885CYP17A1 4475/4885MKNK1 839/4885 |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, MC2R | CYP1A2 260/4885CYP17A1 55/4885MKNK1 1647/4885 |
| US-20100120883-A1 | NOVEL COMPOUNDS | TSLP, LTB4R2, LTB4R | CYP1A2 101/4885CYP17A1 150/4885MKNK1 2300/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | CYP1A2 2366/4885CYP17A1 4109/4885MKNK1 938/4885 |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, TYRO3, IRAK3 | CYP1A2 2279/4885CYP17A1 4417/4885MKNK1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.